Medical billers occasionally run into a persistent myth: that each new COVID-19 variant, whether it’s EG.5, BA.2.86, or whatever strain is circulating this season, comes with its own diagnosis code or billing requirements. It doesn’t. Variant tracking is a genomic surveillance function run by the CDC and state health departments, and it has never translated into a separate ICD-10-CM or HCPCS code for billing purposes.
For the testing side of COVID-19 billing, including specimen collection and diagnostic CPT codes, see this testing-focused breakdown. This post covers the treatment side: what actually changes (and what doesn’t) in antiviral and inpatient billing when a new variant emerges.
The Diagnosis Code Doesn’t Change by Variant
COVID-19 diagnosis coding uses a single code regardless of which lineage a patient is infected with.
U07.1: The Only COVID-19 Diagnosis Code
U07.1 (COVID-19) is the ICD-10-CM code for a confirmed diagnosis, based on a positive molecular or antigen test, or a provider’s documented clinical diagnosis when testing isn’t available. This applies whether the confirmed strain is EG.5, BA.2.86, or any variant that emerges after them. The ICD-10-CM code set has never created variant-specific diagnosis codes, and there’s no indication CMS plans to.
For related presentations, use the appropriate codes alongside U07.1: Z20.822 for confirmed exposure without a positive test, Z11.52 for routine screening with no known exposure, and U09.9 for post-acute sequelae (long COVID) once the acute infection has resolved. Symptom codes such as J22 (unspecified acute lower respiratory infection), R05 (cough), and R50.9 (fever, unspecified) can be added when documentation supports them, but they follow U07.1 in sequence rather than replacing it.
Antiviral Treatment Billing
Coverage and reimbursement for COVID-19 antivirals depend on the drug administered and the setting, not the variant diagnosed.
Remdesivir (Veklury)
Billed under HCPCS code J0248 (Injection, remdesivir, 1 mg) when administered in an outpatient setting, with units reported to reflect the total dosage given. Inpatient administration is typically bundled into the DRG rather than billed separately by the milligram.
Nirmatrelvir/Ritonavir (Paxlovid)
An oral antiviral, dispensed and billed through the pharmacy benefit using its NDC rather than a medical J-code. Coverage varies by payer and whether the government-purchased supply program is still in effect for that plan.
Neither drug’s coverage or coding depends on which variant a patient’s test identifies. What matters for reimbursement is medical necessity, timing of treatment relative to symptom onset, and correct sequencing of U07.1 as the diagnosis supporting the prescription.
Where Billers Actually Need to Stay Current
The parts of COVID-19 billing that do shift over time aren’t variant-specific, they’re payer-specific and policy-specific.
- Prior authorization requirements for antivirals, which some payers have added or removed as treatments moved from emergency use authorization to full FDA approval.
- Monoclonal antibody infusion coverage, which has changed substantially as circulating variants developed resistance to earlier antibody treatments, leading to shifting EUA status rather than new codes.
- Place of service rules for home-administered infusions, which use HCPCS codes such as M0241, M0244, M0246, and M0223 depending on setting, not variant.
- Payer-specific medical necessity documentation, which can require more detail than a positive test alone, particularly for antivirals prescribed outside the standard treatment window.
Tracking payer bulletins for these policy shifts is more useful than watching for new variant names, since the diagnosis and treatment codes themselves stay constant.
Summary
COVID-19 billing hasn’t gotten more complicated with each new variant, it’s stayed the same at the code level while shifting at the policy level. U07.1 remains the diagnosis code regardless of strain, J0248 remains the code for remdesivir, and Paxlovid still runs through the pharmacy benefit. What billers actually need to track is prior authorization changes, monoclonal antibody coverage shifts, and payer-specific documentation requirements, since those are the pieces that move.
Medwave’s billing team stays current on payer policy changes so claims for COVID-19 treatment go out coded correctly the first time, without chasing codes that were never issued.
Co-Founder and COO of Medwave, bringing more than 30 years of hands-on experience in healthcare revenue cycle management, payer contracting, and medical credentialing.